Skip to Main Content

Sierra Oncology said Tuesday that its experimental treatment for the blood cancer myelofibrosis achieved all the efficacy goals of a Phase 3 clinical trial, including an improvement in anemia that currently approved drugs don’t address.

Based on the positive study results, Sierra intends to file a U.S. marketing application for its drug, called momelotinib, during the second quarter. If approved, the drug will enter a myelofibrosis treatment market that is dominated by Jakafi, the Incyte/Novartis drug with sales exceeding $2 billion annually.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment